Gilenya Patent Upheld, But Who's The Biggest Winner – Novartis or Celgene?
Executive Summary
A composition of matter patent for the Novartis MS drug Gilenya expires in 2019, but a recent inter partes review decision upheld a dosing patent that doesn't expire until 2027. However, analysts also touted the victory as a big win for Celgene and its competing S1P modulator ozanimod.
You may also be interested in...
Older Patents Get Help As Federal Circuit Sides With Novartis In Gilenya, Everolimus Disputes
US court finds no obviousness-type double patenting under statute that changed patent term from 17 years from issuance to 20 years from filing; decisions will impact other cases involving patents issued prior to statute.
Novartis's Blockbuster Gilenya Cleared For Children And Adolescents In Europe
Novartis's blockbuster MS drug is now approved for children and adolescent use in the EU as well as the US, as the big pharma continues to build its MS franchise in advance of the start of generic competition to Gilenya, expected sometime after mid-2019.
Cosentyx Carries Novartis Sales But Kymriah Manufacturing Gives Cause For Concern
The Swiss major is very happy indeed with the growth trajectory of Cosentyx and Entresto and pleased with how its migraine drug Aimovig has started. However the revelation of manufacturing problems with its CAR-T therapy Kymriah marred Novartis' second-quarter results.